New combo aims for Drug-Free remission in untreated CLL
NCT ID NCT04458610
First seen Jan 13, 2026 · Last updated May 11, 2026 · Updated 12 times
Summary
This study tests whether combining zanubrutinib (a pill that blocks cancer cell growth) with rituximab (an antibody infusion) can help people with previously untreated chronic lymphocytic leukemia (CLL) achieve a lasting remission without needing ongoing medication. About 60 adults with CLL or small lymphocytic lymphoma will receive the combination, then stop zanubrutinib to see if they stay in remission for at least 6 months. The goal is to control the disease and possibly allow a treatment-free period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.